$RGLS
Regulus Therapeutics Inc. Stock $rgls

$rgls Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000162828023017587 Filed on May 11, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.339M	$2.444M	$2.219M
YoY Change	-5.19%	-15.43%	-13.01%
% of Gross Profit
Research & Development	$4.976M	$4.925M	$4.687M
YoY Change	5.69%	33.87%	7.23%
% of Gross Profit
Depreciation & Amortization	$47.00K	$48.00K	$33.00K
YoY Change	51.61%	84.62%	-19.51%
% of Gross Profit
Operating Expenses	$7.315M	$7.369M	$6.932M
YoY Change	1.95%	12.18%	-0.4%
Operating Profit	-$7.315M	-$7.369M
YoY Change	1.95%	12.18%
Interest Expense	$168.0K	$185.0K	$137.0K
YoY Change	3.7%	19.35%	-179.19%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$7.012M	-$7.139M	-$6.795M
YoY Change	-3.39%	6.27%	-4.74%
Income Tax	$1.000K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$7.013M	-$7.139M	-$6.795M
YoY Change	-3.38%	6.25%	-4.74%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.37	-$0.42
Diluted Earnings Per Share	-$0.37	-$0.42	-$0.40
COMMON SHARES
Basic Shares Outstanding	19.48M shares	16.84M shares	16.84M shares
Diluted Shares Outstanding	19.10M shares	16.84M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$37.26M	$30.31M	$39.16M
YoY Change	-21.61%	-43.77%	-35.15%
Cash & Equivalents	$37.26M	$30.31M	$24.23M
Short-Term Investments	$0.00	$0.00	$14.93M
Other Short-Term Assets	$1.025M	$1.178M	$4.919M
YoY Change	29.75%	23.87%	176.35%
Inventory
Prepaid Expenses	$3.010M	$3.010M	$3.010M
Receivables	$3.000K	$4.000K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$41.36M	$34.56M	$44.08M
YoY Change	-19.52%	-40.34%	-32.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$482.0K	$493.0K	$536.0K
YoY Change	-8.37%	25.13%	90.75%
Goodwill
YoY Change
Intangibles	$39.00K	$58.00K	$62.00K
YoY Change	-44.29%	-21.62%	-25.3%
Long-Term Investments
YoY Change
Other Assets			$0.00
YoY Change			-100.0%
Total Long-Term Assets	$2.284M	$2.453M	$2.637M
YoY Change	-21.3%	-19.63%	-18.08%
TOTAL ASSETS
Total Short-Term Assets	$41.36M	$34.56M	$44.08M
Total Long-Term Assets	$2.284M	$2.453M	$2.637M
Total Assets	$43.65M	$37.02M	$46.72M
YoY Change	-19.62%	-39.3%	-31.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$362.0K	$581.0K	$175.0K
YoY Change	-39.16%	-7.04%	-38.6%
Accrued Expenses	$623.0K	$671.0K	$961.0K
YoY Change	-23.56%	-18.86%	17.05%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.922M	$3.716M	$4.511M
YoY Change	76.88%	349.88%
Total Short-Term Liabilities	$8.229M	$8.822M	$11.66M
YoY Change	41.17%	87.66%	123.02%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$1.421M	$1.598M	$0.00
YoY Change	17.83%	33.95%	-100.0%
Total Long-Term Liabilities	$1.421M	$1.598M	$0.00
YoY Change	-64.48%	-66.58%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.229M	$8.822M	$11.66M
Total Long-Term Liabilities	$1.421M	$1.598M	$0.00
Total Liabilities	$9.650M	$10.42M	$13.43M
YoY Change	-19.12%	-11.27%	-0.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$497.3M	-$490.3M	-$483.2M
YoY Change	6.08%	6.23%	6.23%
Common Stock	$531.3M	$516.9M	$516.5M
YoY Change	3.93%	1.19%	1.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$34.00M	$26.60M	$33.29M
YoY Change
Total Liabilities & Shareholders Equity	$43.65M	$37.02M	$46.72M
YoY Change	-19.62%	-39.3%	-31.76%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$7.013M	-$7.139M	-$6.795M
YoY Change	-3.38%	6.25%	-4.74%
Depreciation, Depletion And Amortization	$47.00K	$48.00K	$33.00K
YoY Change	51.61%	84.62%	-19.51%
Cash From Operating Activities	-$6.252M	-$8.114M	-$6.253M
YoY Change	1.51%	27.16%	-20.15%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$1.000K	$63.00K
YoY Change	-100.0%	-99.02%	-253.66%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$15.00M	$10.53M
YoY Change	-100.0%
Cash From Investing Activities	$0.00	$15.00M	$10.47M
YoY Change	-100.0%	-14804.9%	-25629.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	13.21M	-$805.0K	0.000
YoY Change		-40350.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-6.252M	-$8.114M	-6.253M
Cash From Investing Activities	0.000	$15.00M	10.47M
Cash From Financing Activities	13.21M	-$805.0K	0.000
Net Change In Cash	6.955M	$6.080M	4.214M
YoY Change	-137.03%	-193.81%	-82.82%
FREE CASH FLOW
Cash From Operating Activities	-$6.252M	-$8.114M	-$6.253M
Capital Expenditures	$0.00	$1.000K	$63.00K
Free Cash Flow	-$6.252M	-$8.115M	-$6.316M
YoY Change	4.79%	25.17%	-18.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001505512
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-35670
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Regulus Therapeutics Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-4738379
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	4224 Campus Point Court, Suite 210
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	City Area Code CityAreaCode	858
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	202-6300
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	RGLS
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19475269	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30308000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24228000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	14932000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	62000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	62000	usd
CY2023Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	4000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	0	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3010000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3010000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1178000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1847000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	34562000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	44079000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	493000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	536000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	58000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	62000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1902000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2039000	usd
CY2023Q1	us-gaap	Assets Assets	37015000	usd
CY2022Q4	us-gaap	Assets Assets	46716000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	581000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	175000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	671000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	961000	usd
CY2023Q1	rgls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	538000	usd
CY2022Q4	rgls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	1252000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1022000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2205000	usd
CY2023Q1	us-gaap	Debt Current DebtCurrent	3716000	usd
CY2022Q4	us-gaap	Debt Current DebtCurrent	4511000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2294000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2553000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	8822000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11657000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1598000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1768000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	10420000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	13425000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16859733	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16859733	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16840261	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16840261	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	17000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	17000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	516888000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	516457000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-490315000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-483176000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	26595000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	33291000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	37015000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	46716000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4925000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3679000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2444000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2890000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	7369000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	6569000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7369000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6569000	usd
CY2023Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	415000	usd
CY2022Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	6000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	185000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	155000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7139000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6718000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7139000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-6719000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	12000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7127000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6719000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16844243	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16844243	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14596789	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14596789	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	33291000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	21000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	410000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7139000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	26595000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	54958000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1000000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-6719000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	49241000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7139000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-6719000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	48000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	410000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1000000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-56000	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2023Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	31000	usd
CY2022Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	38000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	4000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	8000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-669000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-681000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	406000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	340000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-290000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-26000	usd
CY2023Q1	rgls	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	-714000	usd
CY2022Q1	rgls	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	-202000	usd
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1183000	usd
CY2022Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1159000	usd
CY2023Q1	rgls	Operating Lease Right Of Use And Lease Liabilities Net Gain Loss OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss	-18000	usd
CY2022Q1	rgls	Operating Lease Right Of Use And Lease Liabilities Net Gain Loss OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss	-12000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-274000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-340000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8114000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6381000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	15000000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	102000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	14999000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-102000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2000	usd
CY2023Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	826000	usd
CY2022Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-805000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6080000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6481000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24290000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60445000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30370000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53964000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30308000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53902000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	62000	usd
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	62000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30370000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53964000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	148000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	110000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	usd
CY2023Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	usd
CY2022Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	33000	usd
CY2023Q1	rgls	Financingfrom Sale Proceeds Debt Agreement Revenues FinancingfromSaleProceedsDebtAgreementRevenues	556600000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	30300000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although </span></div>these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14020658	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13165940	shares
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	29271000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	14944000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	12000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	14932000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	36422000	usd
	rgls	Number Of Amendments NumberOfAmendments	10	amendment
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16859733	shares
CY2023Q1	rgls	Common Stock Voting Rights Votes CommonStockVotingRightsVotes	1	vote
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2052000	shares
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	15097000	shares
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	410000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1000000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	586000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	800000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	824000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	277000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2487000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	225000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2262000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	664000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1598000	usd

Files In Submission

Name	View Source	Status
rgls-20230331_pre.xml	Edgar Link	unprocessable
rgls-20230331_cal.xml	Edgar Link	unprocessable
0001628280-23-017587-index-headers.html	Edgar Link	pending
0001628280-23-017587-index.html	Edgar Link	pending
0001628280-23-017587.txt	Edgar Link	pending
0001628280-23-017587-xbrl.zip	Edgar Link	pending
ex-311x20230331.htm	Edgar Link	pending
ex-312x20230331.htm	Edgar Link	pending
ex-321x20230331.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgls-20230331.htm	Edgar Link	pending
rgls-20230331.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
rgls-20230331_def.xml	Edgar Link	unprocessable
rgls-20230331_lab.xml	Edgar Link	unprocessable
rgls-20230331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGLS
Regulus Therapeutics Inc. Stock $rgls

2023 Q2 Form 10-Q Financial Statement

#000162828023017587 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS Regulus Therapeutics Inc. Stock $rgls

2023 Q2 Form 10-Q Financial Statement

#000162828023017587 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS
Regulus Therapeutics Inc. Stock $rgls